Sanofi announced on February 12, 2026, that it will not renew Paul Hudson's CEO mandate; his last day is February 17, 2026.14
Belén Garijo, outgoing CEO of Merck KGaA, appointed as Sanofi's new CEO starting April 29, 2026; Olivier Charmeil serves as interim CEO.1234
Hudson's six-year tenure saw transformation including Dupixent's rise to blockbuster status, but faced R&D setbacks like FDA rejection of tolebrutinib for MS and failures in Fabry disease and vaccines.123
Sanofi prioritizes strengthening R&D productivity and innovation under Garijo amid pressures from US vaccine policy changes and Dupixent patent expiry in early 2030s.23
No search results confirm recent CEO appointment at Arvinas (PROTAC developer).
Sources:
1. https://www.statnews.com/2026/02/12/sanofi-ceo-replaced-paul-hudson-belen-garijo/
2. https://www.pharmaceutical-technology.com/news/sanofi-replaces-ceo-paul-hudson-with-outgoing-merck-kgaa-head/
3. https://www.biopharmadive.com/news/sanofi-ceo-paul-hudson-belen-garijo/812061/
4. https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-12-06-30-00-3236866